Sir Mene Pangalos Outlines AZ's Trio Of COVID-19 Targets
Testing, Developing Antibodies And Repurposing Medicines
Executive Summary
The diagnostics tie-up with GSK on testing is a near-term move to help the UK get back to normality, the drug major's biopharmaceuticals R&D boss tells Scrip. AstraZeneca's main focus is to develop monoclonal antibodies to tackle 'wave two' of the coronavirus.
You may also be interested in...
From Loser To Leader: The Turnaround Of AstraZeneca
Recently AstraZeneca became the most valuable company by market capitalization on the FTSE 100, quite a switch in fortunes from earlier in the decade, and HR head Fiona Cicconi tells Scrip that a change in culture as well as a productive pipeline has contributed to the firm's recent success.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.